Jul 26, 2023 ¡P Total revenues increased by 36.6% to RMB687.2 million (US$100.0 million) in Fiscal Year 2023 from RMB502.9 million in the same period of 2022.

YS Biopharma Announces Financial Results for Fiscal Year 2023 Ended March 31, 2023. July 26, 2023. YS Biopharma Fiscal Year 2023 Annual Report. Print Page.

Apr 19, 2024 ¡P For the first nine months of our fiscal 2024, we recorded revenues of RMB438.1 million (US$61.9 million), primarily due to the lingering effects of supply ...

Feb 14, 2024 ¡P Cash and cash equivalents of approximately $53 million as of March 31, 2023 , as compared to $42.7 million as of March 31, 2022 ;; Approximately ...

May 13, 2024 ¡P Net cash provided by investing activities was 5,922 million yen (Net cash used by investing activities in the fiscal year ended March 31, 2023 ...

May 9, 2024 ¡P There were differences in the non-consolidated financial results (Japanese standard) between the fiscal year ended March 2024 (April 1, 2023 to March 31, 2024) ...

Apr 25, 2024 ¡P The resulting impacts were a ¥96.3 billion increase in revenue and a ¥19.1 billion increase in core operating profit compared with if the ...

Mar 28, 2024 ¡P Fiscal Year 2023 Financial Results ... Research and development expenses were $64.9 million and $30.4 million for the years ended December 31, ...